BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2015 5:56:00 PM | Browse: 1650 | Download: 2014
 |
Received |
|
2014-03-26 08:30 |
|
Peer-Review Started |
|
2014-03-26 16:42 |
|
To Make the First Decision |
|
2014-04-28 14:13 |
|
Return for Revision |
|
2014-05-03 19:35 |
|
Revised |
|
2014-07-31 07:07 |
|
Second Decision |
|
2014-09-19 08:50 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2014-09-19 09:33 |
|
Articles in Press |
|
2014-09-19 10:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-01-29 18:24 |
|
Publish the Manuscript Online |
|
2015-02-11 17:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Michael S Broder, David Beenhouwer, Jonathan R Strosberg, Maureen P Neary and Dasha Cherepanov |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, United States |
|
|
| Corresponding Author |
Michael S Broder, MD, MSHS, Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, Beverly Hills, CA 90212, United States. mbroder@pharllc.com |
| Key Words |
Carcinoma; Neuroendocrine; Carcinoid syndrome; Carcinoid tumor; Gastrointestinal neoplasms; Neuroendocrine tumor; Antineoplastic agents; Hormonal; Dose-Response relationship; Drug; Octreotide; Literature review; Efficacy; Effectiveness; Symptom control; Tumor progression control; Diarrhea; Abdominal pain; Flushing |
| Core Tip |
Although octreotide-long-acting repeatable (LAR) is Food and Drug Administration approved for alleviating severe diarrhea/flushing associated with metastatic carcinoid tumors at doses ≤ 30 mg every 4 wk, our review found that several studies within the published literature described the use of above-label doses of octreotide-LAR for symptom and tumor control of neuroendocrine tumors. Expert clinical opinion, as reported in this review, supports escalation of somatostatin analogs for patients with refractory hormonal symptoms. |
| Publish Date |
2015-02-11 17:56 |
| Citation |
Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i6.1945 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
